The acute chest syndrome of sickle cell disease

Payal C. Desai, Kenneth Ataga

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Introduction: Acute chest syndrome (ACS), a leading cause of morbidity and mortality in sickle cell disease (SCD), is an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest X-ray. There is increasing knowledge regarding the etiology and pathogenesis of ACS in SCD. A high index of suspicion is required for the diagnosis of ACS. Treatment of ACS involves the judicious use of intravenous fluids and analgesics, aggressive incentive spirometer and pulmonary toileting, antibiotics and transfusion therapy. Areas covered: This review evaluates the epidemiology, clinical and laboratory presentation, etiology and pathogenesis of ACS. It also reviews the standard treatments as well as experimental treatments in ACS. Expert opinion: Despite an increased understanding of its etiology and pathogenesis, ACS remains a leading cause of morbidity and mortality in SCD. In patients admitted with a painful crisis, there is need for a high index of suspicion, as pain episodes may be a prodrome for the development of ACS. Patients with a diagnosis of ACS should be aggressively managed to prevent clinical deterioration. Clinical trials using novel drugs for the treatment of ACS are greatly warranted.

Original languageEnglish (US)
Pages (from-to)991-999
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number8
DOIs
StatePublished - Jun 1 2013

Fingerprint

Acute Chest Syndrome
Sickle Cell Anemia
Morbidity
Therapeutics
Lung
Mortality
Expert Testimony
Analgesics
Motivation
Epidemiology
Fever
Thorax

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

The acute chest syndrome of sickle cell disease. / Desai, Payal C.; Ataga, Kenneth.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 8, 01.06.2013, p. 991-999.

Research output: Contribution to journalReview article

@article{41b2a569546e4a8086878f6215ff3962,
title = "The acute chest syndrome of sickle cell disease",
abstract = "Introduction: Acute chest syndrome (ACS), a leading cause of morbidity and mortality in sickle cell disease (SCD), is an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest X-ray. There is increasing knowledge regarding the etiology and pathogenesis of ACS in SCD. A high index of suspicion is required for the diagnosis of ACS. Treatment of ACS involves the judicious use of intravenous fluids and analgesics, aggressive incentive spirometer and pulmonary toileting, antibiotics and transfusion therapy. Areas covered: This review evaluates the epidemiology, clinical and laboratory presentation, etiology and pathogenesis of ACS. It also reviews the standard treatments as well as experimental treatments in ACS. Expert opinion: Despite an increased understanding of its etiology and pathogenesis, ACS remains a leading cause of morbidity and mortality in SCD. In patients admitted with a painful crisis, there is need for a high index of suspicion, as pain episodes may be a prodrome for the development of ACS. Patients with a diagnosis of ACS should be aggressively managed to prevent clinical deterioration. Clinical trials using novel drugs for the treatment of ACS are greatly warranted.",
author = "Desai, {Payal C.} and Kenneth Ataga",
year = "2013",
month = "6",
day = "1",
doi = "10.1517/14656566.2013.783570",
language = "English (US)",
volume = "14",
pages = "991--999",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - The acute chest syndrome of sickle cell disease

AU - Desai, Payal C.

AU - Ataga, Kenneth

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Introduction: Acute chest syndrome (ACS), a leading cause of morbidity and mortality in sickle cell disease (SCD), is an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest X-ray. There is increasing knowledge regarding the etiology and pathogenesis of ACS in SCD. A high index of suspicion is required for the diagnosis of ACS. Treatment of ACS involves the judicious use of intravenous fluids and analgesics, aggressive incentive spirometer and pulmonary toileting, antibiotics and transfusion therapy. Areas covered: This review evaluates the epidemiology, clinical and laboratory presentation, etiology and pathogenesis of ACS. It also reviews the standard treatments as well as experimental treatments in ACS. Expert opinion: Despite an increased understanding of its etiology and pathogenesis, ACS remains a leading cause of morbidity and mortality in SCD. In patients admitted with a painful crisis, there is need for a high index of suspicion, as pain episodes may be a prodrome for the development of ACS. Patients with a diagnosis of ACS should be aggressively managed to prevent clinical deterioration. Clinical trials using novel drugs for the treatment of ACS are greatly warranted.

AB - Introduction: Acute chest syndrome (ACS), a leading cause of morbidity and mortality in sickle cell disease (SCD), is an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest X-ray. There is increasing knowledge regarding the etiology and pathogenesis of ACS in SCD. A high index of suspicion is required for the diagnosis of ACS. Treatment of ACS involves the judicious use of intravenous fluids and analgesics, aggressive incentive spirometer and pulmonary toileting, antibiotics and transfusion therapy. Areas covered: This review evaluates the epidemiology, clinical and laboratory presentation, etiology and pathogenesis of ACS. It also reviews the standard treatments as well as experimental treatments in ACS. Expert opinion: Despite an increased understanding of its etiology and pathogenesis, ACS remains a leading cause of morbidity and mortality in SCD. In patients admitted with a painful crisis, there is need for a high index of suspicion, as pain episodes may be a prodrome for the development of ACS. Patients with a diagnosis of ACS should be aggressively managed to prevent clinical deterioration. Clinical trials using novel drugs for the treatment of ACS are greatly warranted.

UR - http://www.scopus.com/inward/record.url?scp=84877644197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877644197&partnerID=8YFLogxK

U2 - 10.1517/14656566.2013.783570

DO - 10.1517/14656566.2013.783570

M3 - Review article

VL - 14

SP - 991

EP - 999

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 8

ER -